Friday, May 13, 2022 3:33:40 PM
mRNA vaccine trial data submitted to FDA for EUA, combined in meta-analysis to improve precision and power, finding very low certainty evidence against the use of mRNA vaccines
Dr. Paul Alexander
May 7
A recently reported Danish study by Stabell Benn et al. (not yet peer-reviewed) sought to unravel the impact of mRNA and adenoviral vector COVID vaccines on mortality outcomes and found that the mRNA vaccines failed to save lives (RR 1.03, 95% CI 0.63 to 1.71). A clear benefit was however seen for the adenoviral vector COVID vaccine (RR 0.37, 95% CI 0.19 to 0.70). Their analysis was based on available data and while still pre-print, it has had very serious review by senior global scientists/epidemiologists who have pronounced that the rigor and quality is sufficient. The key is this, that the mRNA vaccines do not confer COVID mortality benefit while the adeno-viral vector vaccine do.
Dr. Martin Kulldorff (prominent vaccine scientist) then commented on this pooled Danish study with a very powerful and crisp commentary, asking a very important question: Have populations been mandated vaccines that fail to save lives and just do not work? I am particularly concerned as a skeptic and contrarian given these mRNA vaccines have now been shown to be ineffective on the Delta and Omicron variants and not properly safe. The Pfizer and Moderna COVID mRNA vaccines do not sterilize the virus (are non-neutralizing as based on the initial Wuhan legacy strain and as such do not match the current variants (spike protein)) in that they do not prevent infection, replication, or transmission. If a vaccine does not cut the chain of transmission in a pandemic of infectious disease, then it cannot achieve herd immunity and is essentially failed.
With this background in place, this analysis by me sought to replicate the Danish finding (conducting the actual meta-analysis) as well as apply GRADE methods to rate the quality of the mortality evidence, culminating in a recommendation for or against the use of the mRNA vaccine in reducing mortality. I also include a rudimentary background on GRADE and apply what can be called ‘GRADE lite’. I simply wished to assess what a GRADE type application to the existing trial data (limited as it may be and of poor methodological quality) would look like since the folk in the EBM world will not apply their expertise to the current body of evidence.
The findings as you see below, cuts against their (medical community, academic scientists, EBMers, CDC, NIH etc.) narrative for two years and certainly on the vaccines. I have learnt that the medical/clinician and academic research community actually practices ‘do not bite the hand that feeds you’ very, very well. They are experts at it. The ‘hand’ is the research grants hand, salaries, career positions etc. To advance their agenda, the key is their agenda, and it is led by the CDC (and the NIH/NIAID), who in the US functions as a political arm of government.
The CDC worked under the Trump administration to undermine him, while works under the Biden administration to support him. They use the MMWR reports to hurt an administration as they wish to and do it by producing bogus incomplete reports with only some of the data and with biased unclear misleading conclusions. They mislead the public and whom within the government they wish to mislead. The data they withheld is not only the 18-49 years old triple booster vaccine data (this is what we have come to know of, there is major more swept under the rug), they are withholding major data and have been doing this all along and IMO it is a real crime. They must be held to account. The reticence by the FDA to make the data available to the public for 55 to 75 years was shocking and showed that there is serious information there that shows much wrong they did. The FDA, CDC, NIH, Pfizer, Moderna and all of their leaders like Bourla and Bancel etc. must be at some point accountable. It must be investigated.
The rest of the article: https://palexander.substack.com/p/grade-methods-applied-to-meta-analysis?s=r
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:21:25 PM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Moderna Resolves Global Patent Litigation with Arbutus/Genevant • ACCESS Newswire • 03/03/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:04:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 02:56:47 PM
- European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 02/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:49:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 03:26:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2026 09:03:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2026 09:02:04 PM
- Moderna to Present at Upcoming Conferences in March 2026 • ACCESS Newswire • 02/19/2026 12:00:00 PM
- Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission • ACCESS Newswire • 02/18/2026 12:00:00 PM
- Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE • ACCESS Newswire • 02/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:41:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 12:02:14 PM
- Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates • ACCESS Newswire • 02/13/2026 12:00:00 PM
- Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 • ACCESS Newswire • 02/10/2026 11:00:00 PM
- Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico • ACCESS Newswire • 02/10/2026 12:00:00 PM
- The $71 Billion Cancer Shift: Why The FDA Is Speeding Up • GlobeNewswire Inc. • 02/05/2026 02:26:03 PM
- Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. • GlobeNewswire Inc. • 02/04/2026 02:15:00 PM
- Dr. David Berman to Join Moderna as Chief Development Officer • ACCESS Newswire • 01/30/2026 12:30:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM


